LIV-1-targeting ADC exerts potent antitumoral activity in murine breast cancer
April 16, 2024
Zinc transporter ZIP6, also known as LIV-1, is a transmembrane protein that is an interesting target for antibody-drug conjugate (ADC) therapy because of its higher expression in tumors and almost no expression in normal tissues.